AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Down 69.5% in December

AstraZeneca PLC (OTCMKTS:AZNCF) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 58,800 shares, a decline of 69.5% from the November 30th total of 192,900 shares. Based on an average daily volume of 6,300 shares, the days-to-cover ratio is currently 9.3 days.

Institutional Trading of AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Eagle Bay Advisors LLC bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 1,001 shares of the company’s stock, valued at approximately $156,000. 40.87% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Trading Up 2.7 %

Shares of AZNCF stock traded up $3.54 during trading hours on Friday, hitting $134.66. The company had a trading volume of 4,124 shares, compared to its average volume of 2,729. AstraZeneca has a 12 month low of $118.16 and a 12 month high of $175.00. The firm’s fifty day moving average is $135.61 and its 200 day moving average is $150.77.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.